SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes

  • Published on 07/02/2024
  •  Reading time: 9 min.

Stepanova Natalia

Department of Nephrology and Dialysis State Institution “O.O. Shalimov National Scientific Center of Surgery and Transplantology of the National Academy of Medical Science of Ukraine” Heroes of Sevastopol 30 03680 Kyiv Ukraine


Peritoneal dialysis (PD) stands as an important modality among kidney replacement therapies for end-stage kidney disease, offering patients remarkable flexibility and autonomy. Despite its widespread use, challenges such as glucose-related complications, peritoneal membrane fibrosis, declining renal function, and cardiovascular risks persist, necessitating innovative therapeutic approaches. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, originally developed for treating...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Nephrology

Receive our newsletter to stay up to date with the latest news in Nephrology

More articles

From peer-reviewed journals in Nephrology